

# Analyzing Disease Mutations in Proteins Involved in Liquid-Liquid Phase Separation

Wendy Olivares 1,3,6, Sueda Cetinkaya1,2, Raymond Zou2, Sairahul Pentaparthi1,4,5,7, Stephen Yi1,4,5,7, Nidhi Sahni1,3

The University of Texas MD Anderson Cancer Center<sup>1</sup>, Bioinformatics and Computational Biology Department<sup>2</sup>, Epigenetics and Molecular Carcinogenesis Department<sup>3</sup>, Livestrong Cancer Institutes<sup>4</sup>, Dell Medical School<sup>5</sup>, Partnership for Careers in Cancer Science and Medicine<sup>6</sup>, **Oncology Department<sup>7</sup>** 

THE UNIVERSITY OF TEXAS MDAnderson Cancer Center

Making Cancer History®

### INTRODUCTION

- Liquid-liquid phase separation (LLPS) is the natural process where a liquid separates into two distinct phases which forms membraneless organelles in cells.
- Condensates can form from high expression, intrinsically disordered regions, multiple folded domains, and other physical properties of proteins.





Fig 1. The different LLPS mechanisms in diseases like cancer and neurodegeneration, as displayed by Alberti et al. (2019)

# **METHODS**

ClinVar presents data on human variation and phenotype and the Human Gene Mutation Database (HGMD) presents mutations associated with human disease.

#### LLPS Protein Databases (DB)





Filtering of

ClinVar &

**HGMD** 


**Systematic** 

**Analyses** 

3

- Using the LLPS UniProt IDs, generate a list of gene names
- Pathogenic clinical significance • Single nucleotide variants
- LLPS Vs. Non-LLPS
- Edgotype Distribution
- Significantly Enriched Diseases
- GOF/LOF

## **SYSTEMATIC ANALYSES RESULTS**



B). When the SHP2/PTPN11 protein is mutated (R362E), there is a change of charge in the area of mutation. PDB: 4DGP Provided by Sueda Cetinkaya C) Three classes of PPI profiles (edgotypes) for mutations as displayed by Sahni et al. (2015)

LLPS Edgotypes

Fig 3. If data was available by Bayrak et al. (2021), mutations were labeled as GOF or LOF with regards to gene expression. Provided by Sueda Cetinkaya




Fig. 4 LLPS & non-LLPS edgotypes

Non-LLPS Edgotypes

Fig 5. Distribution of LLPS mutation enriched diseases for ClinVar Database

### LLPS Enriched Diseases




Fig 6. LLPS Mutation Enriched Diseases for ClinVar database

### CONCLUSION

Overall, we observe significant data associating cancer and neurodegenerative diseases with mutations in LLPS genes based on the HGMD and ClinVar databases.

- There are no significant differences between edgotype characterization of LLPS and non-LLPS gene mutations in HGMD.
- Some of the genes enriched for GOF/LOF mutations include tumor suppressor genes and oncogenes like PTEN and CDKN2A.

# **FUTURE DIRECTIONS**

We acquired promising data in our systematic analyses for further investigating the impact of mutations on protein structure and properties to understand the roles of LLPS in diseases. Joining the structural analyses with our current data and performing the same analyses on cancer mutation databases like The Cancer Genome Atlas will allow us to better understand the roles of mutations in LLPS related diseases.

#### **Acknowledgements**

I would like to thank Dr. Yi and Dr. Sahni for welcoming me into their project and giving me the chance to work with very supportive people. I thank Sueda Cetinkaya for her patience and guidance and always being ready to help. Finally, I would like to thank the department of Women and Minority Faculty Inclusion for allowing me to participate in the Partnerships for Careers in Cancer Science and Medicine program again.

#### References

1) Sahni, Yi et al. Widespread Macromolecular Interaction Perturbations in Human Genetic Disorders 2015;161:647-660 2) Bouchard et al. Cancer Mutations of the tumor suppressor SPOP disrupt the formation of active, phase-separated compartments 2019; 72:19-36 3) Alberti et al. Liquid-Liquid Phase Separation in Disease 2019;59:3.1-3.24 4) Tsang et al. Phase Separation as Missing Mechanism for Interpretation of Disease Mutations 2020;183:1742-1756 5)Bayrak, C. S. et al. 2021. Identification of Discriminative Gene-level & Protein-level Features Associated with Gain-of-Function and Loss-of-Function Mutations. BioRxiv. 6)Zhu, G. et al. 2020. Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation. Cell 183(2 490-502.